Future HIV therapy最新文献

Self-reported low physical function is associated with diabetes mellitus and insulin resistance in HIV-positive and HIV-negative men. 在hiv阳性和hiv阴性的男性中，自我报告的低身体机能与糖尿病和胰岛素抵抗有关。

Future HIV therapy Pub Date : 2008-11-01 DOI: 10.2217/17469600.2.6.539

Allison Longenberger, Jeong Youn Lim, Trevor Orchard, Maria Mori Brooks, Jennifer Brach, Kristen Mertz, Lawrence A Kingsley

{"title":"Self-reported low physical function is associated with diabetes mellitus and insulin resistance in HIV-positive and HIV-negative men.","authors":"Allison Longenberger, Jeong Youn Lim, Trevor Orchard, Maria Mori Brooks, Jennifer Brach, Kristen Mertz, Lawrence A Kingsley","doi":"10.2217/17469600.2.6.539","DOIUrl":"https://doi.org/10.2217/17469600.2.6.539","url":null,"abstract":"Aim: To investigate the association between self-reported physical function (as a surrogate for physical activity) and diabetes mellitus (DM) and insulin resistance (IR) among HIV-positive and -negative men.Method: A total of 384 HIV-negative and 274 HIV-positive men from the Pitt Men's Study contributed data. DM was defined by fasting serum glucose levels. IR was calculated using the homeostasis model assessment. The Physical Functioning 10 Scale from the Short Form-36 Health Survey measured physical function. Multivariate logistic regression assessed the independent association between physical function and DM and IR.Results: Physical function, older age and Black race were associated with DM in multivariate analyses. Physical function/HIV interaction, older age, higher body mass index, HIV infection and Black race were associated with IR in multivariate analyses.Conclusion: Self-reported low physical function is associated with DM and IR in HIV-negative and -positive men.","PeriodicalId":88489,"journal":{"name":"Future HIV therapy","volume":"2 6","pages":"539-549"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/17469600.2.6.539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31537890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection. Etravirine:第二代NNRTI治疗经验的成人耐药HIV-1感染。

Future HIV therapy Pub Date : 2008-11-01 DOI: 10.2217/17469600.2.6.525

Joshua J Minuto, Richard Haubrich

{"title":"Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.","authors":"Joshua J Minuto, Richard Haubrich","doi":"10.2217/17469600.2.6.525","DOIUrl":"https://doi.org/10.2217/17469600.2.6.525","url":null,"abstract":"Etravirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved in the USA in January, 2008, with approval in Europe expected later this year. It is dosed at 200 mg (two 100 mg tablets) twice daily foll owing a meal. It is approved for treatment of HIV-1 infection in adults failing a stable antiretroviral regimen with resistance to other NNRTIs and other antiretroviral agents. Etravirine is active against HIV with single mutations in the reverse transcriptase (e.g., K103N) that confer class resistance to first-generation NNRTIs. Clinical efficacy in Phase III trials has been demonstrated for up to 48 weeks of follow-up. In these Phase III trials, rash was the only adverse event that was significantly more prevalent with etravirine than with placebo. Etravirine has a tolerability and safety profile comparable to placebo with the exception of rash. Rash was generally grade 1 or 2, was not associated with prior NNRTI-related rash, was more common in women than in men, appeared a median of 12 days after treatment initiation and resolved spontaneously with continued therapy. Etravirine is the first agent in the NNRTI class that can be used for HIV-1 virus with resistance to other NNRTIs owing to a higher genetic barrier to resistance.","PeriodicalId":88489,"journal":{"name":"Future HIV therapy","volume":"2 6","pages":"525-537"},"PeriodicalIF":0.0,"publicationDate":"2008-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/17469600.2.6.525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28481588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. 开发治疗hiv相关神经认知功能障碍的神经保护策略。

Future HIV therapy Pub Date : 2008-01-01 DOI: 10.2217/17469600.2.3.271

Jeffrey A Rumbaugh, Joseph Steiner, Ned Sacktor, Avindra Nath

引用次数: 32

Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors. 宿主遗传变异对非核苷类逆转录酶抑制剂药代动力学和临床反应的影响。

Future HIV therapy Pub Date : 2008-01-01 DOI: 10.2217/17469600.2.1.69

Akihiko Saitoh, Stephen A Spector

{"title":"Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.","authors":"Akihiko Saitoh, Stephen A Spector","doi":"10.2217/17469600.2.1.69","DOIUrl":"https://doi.org/10.2217/17469600.2.1.69","url":null,"abstract":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been used widely for treating human immunodeficiency virus type 1 (HIV-1) infected patients as a component of highly active antiretroviral therapy (HAART) and for the prevention of mother-to-child transmission (MTCT). Cytochrome P450 (CYP) 2B6 is an important hepatic isoenzyme responsible for the metabolism of NNRTIs including efavirenz and nevirapine. Recent pharmacogenetic studies have shown that CYP2B6 genetic variants alter hepatic CYP2B6 protein expression and function, and the pharmacokinetics of several CYP2B6 substrates. In particular, the CYP2B6-G516T polymorphism in exon 4 affects the pharmacokinetics of efavirenz. Other studies have shown associations of the CYP2B6-G516T genotype with nevirapine pharmacokinetics and central nervous system adverse effects related to efavirenz use. In total, CYP2B6 genetic variants are important determinants of efavirenz and nevirapine pharmacokinetics . Further studies are needed to identify the associations of CYP2B6 genetic variants with the development of NNRTI resistant viruses.","PeriodicalId":88489,"journal":{"name":"Future HIV therapy","volume":"2 1","pages":"69-81"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/17469600.2.1.69","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29569354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Is male circumcision as good as the HIV vaccine we've been waiting for? 男性包皮环切术和我们期待已久的艾滋病疫苗一样好吗？

Future HIV therapy Pub Date : 2008-01-01 DOI: 10.2217/17469600.2.1.1

Jeffrey D Klausner, Richard G Wamai, Kasonde Bowa, Kawango Agot, Jesse Kagimba, Daniel T Halperin

引用次数: 0